Amyloid β Peptide, Tau aProtein, NGF Metabolism. Early Biomarkers and Associated Mechanisms in Alzheimer´s Diseasec

Chair: Diana Jerusalinsky, Tomas Falzone

[fwduvp preset_id="SAN2020" playlist_id="S02"]
Alzheimer´s disease (AD) is a major neurodegenerative disorder with two forms: the familial, with genetic mutations, and the sporadic affecting people over 65. AD is one of the biggest unresolved health burdens with life expectancy increase. Amyloid β (Aβ) peptide deposition may begin 20 years before and neurobrillary degeneration could be present 10 years prior to onset of memory loss. The finding of AD biomarkers has enabled a molecular definition of AD: ATN (Amyloid, Tau, Neurodegeneration). This Symposium is aimed to show different approaches to analyze relevant biomolecules roles, as from Aβ effect in neurodevelopment and neurodegeneration, artificial humanized organoids to analyze changes in axonal transport involving tau protein, the NGF metabolism as a preclinical AD signal evidenced in body fluids, to finalize with biomarkers imaging and associated cognitive impairments in patients, to discuss and interpret molecular and metabolic mechanisms and their relationship with early biomarkers associated to pre-Dementia stages. There will be four lectures: 1) Amyloid beta oligomers in neural development and degeneration 2) From balanced axonal transport in health, to impaired dynamics in human models of tauopathies: untangling the road to neurodegeneration. 3) The deregulation of the NGF metabolism is present as from preclinical AD and it is revealed in body fluids. 4) Cognitive studies and biomarkers in predementia stages of patients with AD.